Can Aging Intestines Heal? CAR T-Cell Therapy Sparks New Hope for Gut Regeneration

By Stayinghealthy !
CAR T-cells targeting senescent cells to regenerate aging intestinal tissue and restore gut health
*CAR T-cell therapy removes senescent cells, allowing intestinal stem cells to regenerate damaged gut tissue / Freepik 


Aging and damage to the intestinal lining have long been linked with digestive dysfunction, chronic inflammation, and reduced nutrient absorption. Recent scientific discoveries have uncovered an innovative approach using advanced immunotherapy — originally developed for cancer treatment — to rejuvenate aging intestines and restore intestinal health.

Why Intestinal Health Declines With Age

The intestine plays a vital role in digestion and overall health. Its inner lining, known as the intestinal epithelium, is responsible for nutrient absorption and forming a protective barrier against harmful microbes and toxins. Under ideal conditions, this epithelial layer naturally regenerates itself every three to five days.

However, with aging or following cancer treatment like radiation therapy, this regenerative capacity declines. As a result:

  • Inflammation increases.
  • The intestinal barrier weakens, contributing to conditions such as “leaky gut syndrome.”
  • Digestive symptoms and immune dysfunction become more common.

The science behind this decline centers partly on the progressive accumulation of senescent cells — cells that have stopped dividing but do not die and instead release inflammatory signals that disrupt normal tissue function.

CAR T-Cell Immunotherapy: From Cancer to Gut Regeneration

Chimeric antigen receptor (CAR) T-cell therapy has revolutionized treatment for certain blood cancers by reprogramming T cells to specifically target malignant cells. Now, researchers are testing whether similar technology can help remove senescent cells that accumulate in aging tissues — including the intestines. 

A team of scientists from Cold Spring Harbor Laboratory in New York has published evidence in Nature Aging showing that CAR T-cell therapy targeting senescence-associated markers can improve intestinal regeneration in aged mice. 

How CAR T Cells Work in This Context

The therapy involves engineering T cells to recognize and eliminate cells that express the urokinase plasminogen activator receptor (uPAR), a protein commonly found on senescent cells. By clearing these dysfunctional cells from the gut environment, the intestine’s natural stem cells can better regenerate the epithelium, leading to reduced inflammation and improved function. 

In experimental models, this immunotherapy showed promising effects:

  • Enhanced intestinal tissue regeneration.
  • Lowered inflammatory markers in the gut.
  • Improved nutrient absorption and epithelial healing after injury.

Remarkably, a single CAR T-cell treatment improved intestinal health for up to one year in animal models. 

Animal Models Demonstrate Strong Regenerative Outcomes

In the Cold Spring Harbor Laboratory study, researchers administered anti-uPAR CAR T cells directly to the intestines of both younger and older mice. The results were striking:

  • Both age groups showed accelerated epithelial regeneration.
  • Inflammation decreased significantly in treated animals.
  • Intestinal barrier function improved even after radiation-induced damage — a model that simulates cancer therapy effects. 

Treated mice exhibited better nutrient absorption and resilience following gut injury compared to control animals. These effects were sustained long term, marking a potential paradigm shift in how aging intestinal disorders are approached.

Proof of Concept: Human Intestinal Cells Respond

In addition to animal studies, preliminary laboratory experiments using human intestinal and colorectal cell cultures indicate that anti-uPAR CAR T cells may similarly enhance tissue regeneration in human tissues. While clinical trials are still needed, this early evidence strengthens the potential for future therapeutic applications. 

Underlying Mechanisms: What Science Tells Us

Intestinal stem cells (ISCs) are essential for gut epithelium renewal. With age, senescent cells accumulate within the ISC niche, inhibiting their function and leading to slower regeneration. Targeting these cells with senolytic CAR T therapy appears to remove this barrier, restoring stem cell activity and supporting healthier intestinal architecture.

Senescent cells also contribute to inflammaging, an age-related chronic inflammatory state that damages tissues throughout the body. By selectively eliminating senescent cells, CAR T therapy may mitigate this harmful inflammatory milieu. 

Beyond the Gut: Broader Age-Related Implications

While intestinal regeneration is a major focus, the concept of using engineered T cells to eliminate senescent cells has broader implications for aging biology. Other studies suggest that targeted CAR T strategies can influence metabolic aging and overall tissue function.

For example, similar senolytic CAR T approaches have been used in mouse models to reduce signs of metabolic age-related dysfunction, reinforcing the potential of this technology beyond a single organ system. 

Current Limitations and Future Directions

Despite these encouraging findings, several challenges remain before this research translates into human therapies:

  • Human Clinical Trials: Human trials are crucial to determine safety and efficacy in people.
  • Immune System Variation: Age alters immune responses and may affect CAR T persistence and performance in older patients. 
  • Long-Term Safety: Ensuring that engineered T cells do not cause off-target effects is essential.

Expert Perspectives

Researchers involved in this cutting-edge work emphasize that while CAR T therapy is still in early stages for aging interventions, the results represent a significant step in understanding and potentially treating age-related dysfunction in the gut and beyond. 

According to co-investigator Semir Beyaz, this strategy may one day help improve quality of life for both older adults and cancer survivors grappling with gastrointestinal side effects of radiation therapies. 

Conclusion: A Promising Path for Gut Regeneration

Emerging research into CAR T-cell immunotherapy has opened a promising new avenue for healing aging intestines and supporting gut health. While challenges remain, the ability of engineered T cells to remove senescent cells and stimulate intestinal regeneration represents a potential breakthrough in aging biology and therapeutic development.

As scientists continue to refine and test these approaches, the dream of restoring gut resilience in the elderly and mitigating long-term effects of cancer treatment may soon move from the lab into clinical reality.

References